^
    6d
    Study of the blood-brain barrier-penetrating KRAS G12C inhibitor JMKX1899 in KRAS G12C-mutated NSCLC with brain metastases. (PubMed, J Natl Cancer Cent)
    JMKX1899 selectively inhibited cell viability across multiple KRAS G12C-mutant cell lines, exhibiting slightly greater potency than AMG510 and MRTX849. Early clinical data from KRAS G12C-mutant NSCLC patients with BM treated by JMXK1899 further confirm its blood-brain barrier penetration and antitumor activity. These findings strongly support the continued clinical development of JMKX1899 as a promising therapeutic candidate for NSCLC patients with KRAS G12C mutations and BM.
    Journal
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation
    |
    Lumakras (sotorasib) • Krazati (adagrasib) • sosimerasib (HBI-2438)
    7ms
    Phase 3 Trial of JMKX001899 Versus Docetaxel in Previously Treated Advanced or Metastatic KRAS G12C-Mutant NSCLC (clinicaltrials.gov)
    P3, N=472, Not yet recruiting, Jemincare
    New P3 trial
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    docetaxel • sosimerasib (HBI-2438)
    9ms
    A Dose Escalation Study of HBI-2438 in Patients With Solid Tumors Harboring KRAS G12C Mutation (clinicaltrials.gov)
    P1, N=44, Active, not recruiting, HUYABIO International, LLC. | Recruiting --> Active, not recruiting | Trial completion date: Aug 2025 --> Dec 2026 | Trial primary completion date: Aug 2025 --> Dec 2026
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation • KRAS G12C • KRAS G12
    |
    sosimerasib (HBI-2438)
    12ms
    A Phase Ib Study of JMKX001899 in Combination With Other Therapies in Advanced NSCLC Harboring KRAS G12C Mutation (clinicaltrials.gov)
    P1, N=72, Recruiting, Jemincare | Not yet recruiting --> Recruiting
    Enrollment open
    |
    carboplatin • pemetrexed • ifebemtinib (IN10018) • sosimerasib (HBI-2438)
    1year
    A Phase Ib Study of JMKX001899 in Combination With Other Therapies in Advanced NSCLC Harboring KRAS G12C Mutation (clinicaltrials.gov)
    P1, N=72, Not yet recruiting, Jemincare
    New P1 trial
    |
    carboplatin • pemetrexed • ifebemtinib (IN10018) • sosimerasib (HBI-2438)
    almost2years
    To Assess the Effects of Single Dose of JMKX001899 on QTc Interval in Healthy Subjects (clinicaltrials.gov)
    P1, N=27, Not yet recruiting, Jemincare
    New P1 trial
    |
    sosimerasib (HBI-2438)
    2years
    Study to Evaluate the Drug-drug Interaction of JMKX001899 in Healthy Subjects (clinicaltrials.gov)
    P1, N=72, Not yet recruiting, Jemincare
    New P1 trial
    |
    itraconazole • midazolam hydrochloride • rifampicin • sosimerasib (HBI-2438)
    over3years
    A Dose Escalation Study of HBI-2438 in Patients With Solid Tumors Harboring KRAS G12C Mutation (clinicaltrials.gov)
    P1, N=44, Recruiting, HUYABIO International, LLC. | Not yet recruiting --> Recruiting
    Enrollment open • Metastases
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation • KRAS G12C • KRAS G12
    |
    sosimerasib (HBI-2438)
    almost4years
    A Dose Escalation Study of HBI-2438 in Patients With Solid Tumors Harboring KRAS G12C Mutation (clinicaltrials.gov)
    P1, N=44, Not yet recruiting, HUYABIO International, LLC.
    New P1 trial
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation • KRAS G12C • KRAS G12
    |
    sosimerasib (HBI-2438)